Jimma University Open access Institutional Repository

Therapeutic efficacy of chloroquine for treatment Of plasmodium vivax malaria among outpatients at Hossana health center, southern ethiopia

Show simple item record

dc.contributor.author Mesfin assefa
dc.contributor.author Abdisa biruksew
dc.contributor.author Teferi eshetu
dc.date.accessioned 2020-12-07T12:15:15Z
dc.date.available 2020-12-07T12:15:15Z
dc.date.issued 2014-11
dc.identifier.uri http://10.140.5.162//handle/123456789/1840
dc.description.abstract Background: Plasmodium vivax accounts for about 44 % of all malaria infection in Ethiopia. Chloroquine is the first line treatment of Plasmodium vivax malaria in Ethiopia. However, chloroquine is first line drug used to treat P.vivax malaria in Ethiopia, some reports indicating the emergence of chloroquine resistant vivax malaria in different parts of the country. Chloroquine resistant Plasmodium vivax has been emerging in different parts of the world, and posing both health and economic impact especially in developing countries. Objective: To determine therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients in Hossana Health centre, Southern Ethiopia. Methods: A one arm 28 days in vivo drug efficacy study was conducted at Hossana Health Centre from April 5 to June 25/2014. Convenient sampling technique was used to enrol 63 patients aged between 4 and 59 years with microscopically confirmed Plasmodium vivax. All patients were treated with chloroquine 25 mg/kg for three days. Recurrence of parasitaemia and clinical conditions of patients were assessed on day 1, 2, 3, 7, 14, 21, and 28 during the 28 day follow-up period. Haemoglobin level was determined on day 0, day 28 and on day of recurrence of parasitaemia by using portable spectrophotometer. Results: From 63 patients included in the study, 60 (95.2%) completed their 28 days follow up, 3 patients excluded from the study;1 patient due to vomiting of the second dose of drug, 1 patient due to Plasmodium falciparum infection and 1 patient lost to follow up the study. During enrolment, 35(53.3 %) had a history of fever and 28(46.7 %) had documented fever. The geometric mean of parasite density on day of enrolment was 3472 parasites/μl. Among these, 2 patients had recurrent parasitaemia within the 28 day follow up. Conclusion: Chloroquine was found to be efficacious (96.7%) except 2 treatment failures detected in Hossana Health Centre Southern Ethiopia This failure is most likely late parasitological failure. Recommendation: Regular monitoring of the pattern of resistance to chloroquine is needed in Plasmodium vivax malaria endemic areas of the country to take measures rapidly and effectively to control the possible spread of drug resistance en_US
dc.language.iso en en_US
dc.subject Plasmodium vivax en_US
dc.subject Chloroquine resistance en_US
dc.subject therapeutic efficac en_US
dc.subject Ethiopia en_US
dc.title Therapeutic efficacy of chloroquine for treatment Of plasmodium vivax malaria among outpatients at Hossana health center, southern ethiopia en_US
dc.type Thesis en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search IR


Browse

My Account